Robin Bechhofer

865 total citations
18 papers, 681 citations indexed

About

Robin Bechhofer is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Robin Bechhofer has authored 18 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 9 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Robin Bechhofer's work include Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Robin Bechhofer is often cited by papers focused on Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Robin Bechhofer collaborates with scholars based in United States. Robin Bechhofer's co-authors include Barry E. Storer, Peter Köhler, Paul M. Sondel, Jacquelyn A. Hank, J A Hank, Kate H. Moore, Jeff Sosman, Nancy S. Rosenthal, Jeffrey A. Sosman and Paul M. Sondel and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer and Annals of Emergency Medicine.

In The Last Decade

Robin Bechhofer

18 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Bechhofer United States	14	442	333	93	70	68	18	681
SJ Goldman United States	9	267 0.6×	166 0.5×	143 1.5×	21 0.3×	34 0.5×	12	595
D. Scott Batty United States	11	514 1.2×	61 0.2×	83 0.9×	44 0.6×	81 1.2×	13	1.1k
C. W. Steiner Austria	11	455 1.0×	101 0.3×	141 1.5×	58 0.8×	18 0.3×	13	681
P. Reekers Netherlands	12	370 0.8×	79 0.2×	163 1.8×	229 3.3×	34 0.5×	30	720
M Schneider France	12	102 0.2×	446 1.3×	196 2.1×	41 0.6×	37 0.5×	54	759
Louis A. VanderMolen United States	12	158 0.4×	220 0.7×	56 0.6×	20 0.3×	19 0.3×	23	382
Emma Vernon United States	5	176 0.4×	103 0.3×	63 0.7×	59 0.8×	29 0.4×	9	738
Peter Waldron United States	13	109 0.2×	117 0.4×	155 1.7×	55 0.8×	16 0.2×	30	641
Arianna Damiani Italy	13	180 0.4×	86 0.3×	66 0.7×	103 1.5×	38 0.6×	55	633
Francesca Li Gobbi Italy	13	231 0.5×	65 0.2×	59 0.6×	120 1.7×	39 0.6×	59	644

Countries citing papers authored by Robin Bechhofer

Since Specialization

Citations

This map shows the geographic impact of Robin Bechhofer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Bechhofer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Bechhofer more than expected).

Fields of papers citing papers by Robin Bechhofer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Bechhofer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Bechhofer. The network helps show where Robin Bechhofer may publish in the future.

Co-authorship network of co-authors of Robin Bechhofer

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Bechhofer. A scholar is included among the top collaborators of Robin Bechhofer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Bechhofer. Robin Bechhofer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Buhr, Kevin A., et al.. (2017). Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility. Therapeutic Innovation & Regulatory Science. 52(4). 459–468. 12 indexed citations

Lewis, Roger, Donald A. Berry, Henry Cryer, et al.. (2001). Monitoring a clinical trial conducted under the food and drug administration regulations allowing a waiver of prospective informed consent: The diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. Annals of Emergency Medicine. 38(4). 397–404. 35 indexed citations

Albertini, Mark R., Jacquelyn A. Hank, Joan H. Schiller, et al.. (1997). Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.. PubMed. 3(8). 1277–88. 59 indexed citations

Hank, Jacquelyn A., Mark R. Albertini, Joan H. Schiller, et al.. (1995). Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.. PubMed. 1(5). 481–91. 16 indexed citations

Schiller, Joan H., Jacquelyn A. Hank, Barry E. Storer, et al.. (1993). A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.. PubMed. 53(6). 1286–92. 24 indexed citations

Gambacorti‐Passerini, Carlo, Jacquelyn A. Hank, Mark R. Albertini, et al.. (1993). A Pilot Phase II Trial of Continuous-Infusion Interleukin-2 Followed by Lymphokine-Activated Killer Cell Therapy and Bolus-Infusion Interleukin-2 in Renal Cancer. Journal of Immunotherapy. 13(1). 43–48. 7 indexed citations

Voss, Stephan D., et al.. (1992). Serum CD25 Levels During Interleukin-2 Therapy. Journal of Immunotherapy. 11(2). 111–118. 20 indexed citations

Sosman, Jeff, Kathleen Schell, Peter Köhler, et al.. (1991). Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom. Cancer Investigation. 9(1). 35–48. 12 indexed citations

Albertini, Mark R., Jeffrey A. Sosman, Jacquelyn A. Hank, et al.. (1990). the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer. 66(12). 2457–2464. 27 indexed citations

10.

Hank, Jacquelyn A., et al.. (1990). Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.. PubMed. 9(1). 5–14. 19 indexed citations

11.

Köhler, Peter, Jacquelyn A. Hank, Barry E. Storer, et al.. (1989). Phase 1 Clinical Trial of Recombinant Interleukin-2: A Comparison of Bolus and Continuous Intravenous Infusion. Cancer Investigation. 7(3). 213–223. 28 indexed citations

12.

Goldstein, Daniel A., Jeff Sosman, Jacquelyn A. Hank, et al.. (1989). Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.. PubMed. 49(23). 6832–9. 19 indexed citations

13.

Moore, Kate H., et al.. (1988). The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.. PubMed. 7(2). 123–39. 18 indexed citations

14.

Sosman, Jeffrey A., Peter Köhler, Jacquelyn A. Hank, et al.. (1988). Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1. JNCI Journal of the National Cancer Institute. 80(1). 60–63. 107 indexed citations

15.

Sosman, Jeff, Peter Köhler, J A Hank, et al.. (1988). Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin. JNCI Journal of the National Cancer Institute. 80(18). 1451–1461. 75 indexed citations

16.

Sondel, Paul M., Peter Köhler, J A Hank, et al.. (1988). Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.. PubMed. 48(9). 2561–7. 132 indexed citations

17.

Hank, J A, Peter Köhler, G Weil-Hillman, et al.. (1988). In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.. PubMed. 48(7). 1965–71. 65 indexed citations

18.

Moore, Kate H., et al.. (1987). Phase 1 clinical evaluation of recombinant interleukin-2.. PubMed. 244. 161–72. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact